UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Molecular Pathways: Next-Generation Immunotherapy― Inhibiting Programmed Death-Ligand 1 and Programmed Death-1

Clinical cancer research, 2012-12, Vol.18 (24), p.6580-6587

2012

Volltextzugriff (PDF)

Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors

Nature cancer, 2023-04, Vol.4 (4), p.485-501

2023

Volltextzugriff (PDF)

Role of PD-1 during effector CD8 T cell differentiation

Proceedings of the National Academy of Sciences - PNAS, 2018-05, Vol.115 (18), p.4749-4754

2018

Volltextzugriff (PDF)

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade

Immunity (Cambridge, Mass.), 2016-03, Vol.44 (3), p.609-621

2016

Volltextzugriff (PDF)

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016

Journal for Immunotherapy of Cancer, 2017-06, Vol.5 (1), p.50-50, Article 50

2017

Volltextzugriff (PDF)

Abstract 3211: PD-1-targeted Probody therapeutics provide anti-tumor efficacy and a 10-fold dose protection against systemic autoimmunity in preclinical studies

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3211-3211

2016

Volltextzugriff (PDF)

Thymocyte Development in the Absence of Pre-T Cell Receptor Extracellular Immunoglobulin Domains

Science (American Association for the Advancement of Science), 1998-05, Vol.280 (5365), p.905-908

1998

Volltextzugriff (PDF)

Sequential Interactions of the TCR with Two Distinct Cytoplasmic Tyrosine Kinases

Science (American Association for the Advancement of Science), 1994-02, Vol.263 (5150), p.1136-1139

1994

Volltextzugriff (PDF)

Regulation of Interleukin-2 Gene Enhancer Activity by the T Cell Accessory Molecule CD28

Science (American Association for the Advancement of Science), 1991-01, Vol.251 (4991), p.313-316

1991

Volltextzugriff (PDF)

Abstract P193: AMX-818, a novel prodrug HER2-XPAT T-cell engager (TCE) with potent T cell activation, proteolytic cleavage and efficacy in xenograft tumors, and wide safety margins in NHP (Non Human Primate)

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P193-P193

2021

Volltextzugriff (PDF)

Signaling checkpoints during the development of T lymphocytes

Current opinion in immunology, 1998-06, Vol.10 (3), p.360-367

1998

Volltextzugriff (PDF)

Abstract A164: EGFR-CD3 bispecific Probody™ therapeutic induces tumor regressions and increases maximum tolerated dose >60-fold in preclinical studies

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.A164-A164

2018

Volltextzugriff (PDF)

Abstract A203: CD3-EGFR bispecific Probody™ therapeutics induced tumor regressions and increased therapeutic window in preclinical studies

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.A203-A203

2015

Volltextzugriff (PDF)

Pillars article: Sequential interactions of the TCR with two distinct cytoplasmic tyrosine kinases. Science. 1994. 263: 1136-1139

The Journal of immunology (1950), 2014-11, Vol.193 (9), p.4279-4282

2014

Volltextzugriff (PDF)

Abstract LB-288: A phase I study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.LB-288-LB-288

2013

Volltextzugriff (PDF)

The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathways

Cell, 1991-03, Vol.64 (5), p.891-901

1991

Volltextzugriff (PDF)

Abstract A081: A PD-L1-targeted Probody provides antitumor efficacy while minimizing induction of systemic autoimmunity

Cancer immunology research, 2016-01, Vol.4 (1_Supplement), p.A081-A081

2016

Volltextzugriff (PDF)

Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.3001-3001

2013

Volltextzugriff (PDF)

MAP kinase inhibitors stimulate T cell and anti-tumor activity in combination with blockade of the PD-L1/PD-1 interaction

Journal for immunotherapy of cancer, 2013-11, Vol.1 (S1), p.P79-P79, Article P79

2013

Volltextzugriff (PDF)

Functional characterization of a signal transducing motif present in the T cell antigen receptor ζ chain

The Journal of experimental medicine, 1993-04, Vol.177 (4), p.1093-1103

1993

Volltextzugriff (PDF)

The ζ Chain is Associated with a Tyrosine Kinase and Upon T-Cell Antigen Receptor Stimulation Associates with ZAP-70, a 70-kDa Tyrosine Phosphoprotein

Proceedings of the National Academy of Sciences - PNAS, 1991-10, Vol.88 (20), p.9166-9170

1991

Volltextzugriff (PDF)

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31 st Annual Meeting of the Society for Immunotherapy of Cancer, 2016

Journal for immunotherapy of cancer, 2017, Vol.5, p.50

2017

Volltextzugriff (PDF)

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

Journal for immunotherapy of cancer, 2016-11, Vol.4 (S1), p.107-221, Article 73

2016

Volltextzugriff (PDF)

Interaction of the unique N-terminal region of tyrosine kinase p56lck with cytoplasmic domains of CD4 and CD8 is mediated by cysteine motifs

Cell, 1990-03, Vol.60 (5), p.755-765

1990

Volltextzugriff (PDF)

Surface chimeric receptors as tools in study of lymphocyte activation

Methods in Enzymology, 2000, Vol.327, p.210-228

2000

Volltextzugriff (PDF)

1 – 25 von 209

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(192)
Mit Volltextzugriff
(188)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(207)
Japanisch
(23)
Deutsch
(1)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(83)
Life Sciences & Biomedicine
(62)
Humans
(58)
Animals
(41)
Mice
(27)
Female
(24)
Male
(21)
Signal Transduction
(20)
Biological And Medical Sciences
(19)
Immunology
(14)
Science & Technology - Other Topics
(13)
Multidisciplinary Sciences
(12)
Oncology
(12)
Cell Line
(10)
Fundamental And Applied Biological Sciences. Psychology
(10)
Mice, Inbred C57bl
(10)
Middle Aged
(10)
Physical Sciences
(10)
Adult
(9)
Amino Acid Sequence
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Molecular Pathways: Next-Generation Immunotherapy― Inhibiting Programmed Death-Ligand 1 and Programmed Death-1

Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors

Role of PD-1 during effector CD8 T cell differentiation

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016

Abstract 3211: PD-1-targeted Probody therapeutics provide anti-tumor efficacy and a 10-fold dose protection against systemic autoimmunity in preclinical studies

Thymocyte Development in the Absence of Pre-T Cell Receptor Extracellular Immunoglobulin Domains

Sequential Interactions of the TCR with Two Distinct Cytoplasmic Tyrosine Kinases

Regulation of Interleukin-2 Gene Enhancer Activity by the T Cell Accessory Molecule CD28

Abstract P193: AMX-818, a novel prodrug HER2-XPAT T-cell engager (TCE) with potent T cell activation, proteolytic cleavage and efficacy in xenograft tumors, and wide safety margins in NHP (Non Human Primate)

Signaling checkpoints during the development of T lymphocytes

Abstract A164: EGFR-CD3 bispecific Probody™ therapeutic induces tumor regressions and increases maximum tolerated dose >60-fold in preclinical studies

Abstract A203: CD3-EGFR bispecific Probody™ therapeutics induced tumor regressions and increased therapeutic window in preclinical studies

Pillars article: Sequential interactions of the TCR with two distinct cytoplasmic tyrosine kinases. Science. 1994. 263: 1136-1139

Abstract LB-288: A phase I study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors

The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathways

Abstract A081: A PD-L1-targeted Probody provides antitumor efficacy while minimizing induction of systemic autoimmunity

Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study

MAP kinase inhibitors stimulate T cell and anti-tumor activity in combination with blockade of the PD-L1/PD-1 interaction

Functional characterization of a signal transducing motif present in the T cell antigen receptor ζ chain

The ζ Chain is Associated with a Tyrosine Kinase and Upon T-Cell Antigen Receptor Stimulation Associates with ZAP-70, a 70-kDa Tyrosine Phosphoprotein

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31 st Annual Meeting of the Society for Immunotherapy of Cancer, 2016

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

Interaction of the unique N-terminal region of tyrosine kinase p56lck with cytoplasmic domains of CD4 and CD8 is mediated by cysteine motifs

Surface chimeric receptors as tools in study of lymphocyte activation

Suchergebnisse filtern